BrainsWay Ltd. (BWAY)
| Market Cap | 29.48M |
| Revenue (ttm) | 25.83M |
| Net Income (ttm) | -13.79M |
| Shares Out | 17.13M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 23,035 |
| Open | 1.76 |
| Previous Close | 1.73 |
| Day's Range | 1.71 - 1.76 |
| 52-Week Range | 1.38 - 7.00 |
| Beta | 0.15 |
| Analysts | Strong Buy |
| Price Target | 6.25 (+263.16%) |
| Earnings Date | May 17, 2023 |
About BWAY
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company prim... [Read more]
Financial Performance
In 2022, Brainsway's revenue was $27.18 million, a decrease of -8.36% compared to the previous year's $29.66 million. Losses were -$13.35 million, 106.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for BWAY stock is "Strong Buy." The 12-month stock price forecast is $6.25, which is an increase of 263.16% from the latest price.
News
BrainsWay Announces Appointment of Ido Marom as CFO
BURLINGTON, Mass. and JERUSALEM, May 23, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...
BrainsWay Reports First Quarter 2023 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, May 17, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain d...
BrainsWay Launches Investigator Initiated Study (IIS) Program
Application Period Open for Data Collaboration and Equipment Loan Initiatives Application Period Open for Data Collaboration and Equipment Loan Initiatives
BrainsWay to Report First Quarter 2023 Financial Results on May 17, 2023
BURLINGTON, Mass. and JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...
BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression
Real-World Evidence Demonstrates the Highest Response and Remission Rates Observed to Date for Deep
BrainsWay Reports Fourth Quarter and Full-Year 2022 Financial Results and Operational Highlights
BURLINGTON, Mass. and JERUSALEM, March 15, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain...
BrainsWay to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023
BURLINGTON, Mass. and JERUSALEM, Israel, March 01, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulatio...
BrainsWay Announces Appointment of Hadar Levy as CEO
BURLINGTON, Mass. and JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Announces Appointment of Ami Boehm as New Chairman
David Zacut, M.D., Relinquishing Chairman Role Held Since Company's Inception, to Now Serve as Board Director David Zacut, M.D., Relinquishing Chairman Role Held Since Company's Inception, to Now Serv...
BrainsWay Announces Extended Private Insurance Coverage in Washington State for the Treatment of OCD and Depression Utilizing Deep TMS™
BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Resolves Neuronetics Litigation
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain ...
BrainsWay Reports Open Market Stock Purchase by Board Member Yossi Ben Shalom
BURLINGTON, Mass. and JERUSALEM, Dec. 13, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain ...
BrainsWay Reports Open Market Stock Purchases by Two Board Members
BURLINGTON, Mass. and JERUSALEM, Nov. 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and non-invasive treatment for brain ...
BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights
Conference call to be held today, November 16, 2022, at 8:30 AM ET Conference call to be held today, November 16, 2022, at 8:30 AM ET
BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™
Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression Patients Reflects Broader Trends Significantly Increasing Access to Deep TMS for OCD and Depression Patients
BrainsWay to Report Third Quarter Financial Results on November 16, 2022
BURLINGTON, Mass. and JERUSALEM, Nov. 02, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs
Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years Dr. Hanlon has Served as a Leader in Brain Stimulation Research for Nearly 20 Years
BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley
BURLINGTON, Mass. and JERUSALEM, Sept. 20, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a world leader in advanced and noninvasive treatment for brain ...
BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™
Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsive Disorder Cigna® Issues Favorable Policy for Deep TMS to Address Medication-Resistant Obsessive-Compulsi...
BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference
BURLINGTON, Mass. and JERUSALEM, Aug. 31, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced and non-invasive treatment for brain...
BrainsWay Receives New FDA Clearance for Treating Depression and Anxious Depression
Depression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company's 9th FDA Clearance Depression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company's 9th FDA Cleara...
BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights
Revenue Growth of 14% Year-over-Year in Q2 2022
BrainsWay to Report Second Quarter Financial Results on August 10, 2022
BURLINGTON, Mass. and JERUSALEM, July 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...
BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression
The Company's Groundbreaking Deep TMS™ Treatment is Included in Israel's Health Basket of Essential Medical Services The Company's Groundbreaking Deep TMS™ Treatment is Included in Israel's Health Bas...
BrainsWay to Present at the H.C. Wainwright 1st Annual Mental Health Conference
BURLINGTON, Mass. and JERUSALEM, June 22, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatme...